Bellevue Life Sciences Acquisition (BLAC) Competitors $1.67 +0.22 (+15.17%) As of 06/10/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock BLAC vs. NXL, QTI, LYRA, FEMY, CLGN, ALUR, RVP, BBLG, NRXS, and NXGLShould you be buying Bellevue Life Sciences Acquisition stock or one of its competitors? The main competitors of Bellevue Life Sciences Acquisition include Nexalin Technology (NXL), QT Imaging (QTI), Lyra Therapeutics (LYRA), Femasys (FEMY), CollPlant Biotechnologies (CLGN), Allurion Technologies (ALUR), Retractable Technologies (RVP), Bone Biologics (BBLG), NeurAxis (NRXS), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry. Bellevue Life Sciences Acquisition vs. Its Competitors Nexalin Technology QT Imaging Lyra Therapeutics Femasys CollPlant Biotechnologies Allurion Technologies Retractable Technologies Bone Biologics NeurAxis NEXGEL Nexalin Technology (NASDAQ:NXL) and Bellevue Life Sciences Acquisition (NASDAQ:BLAC) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, institutional ownership, analyst recommendations, community ranking, profitability, risk and earnings. Which has more volatility & risk, NXL or BLAC? Nexalin Technology has a beta of 4, indicating that its stock price is 300% more volatile than the S&P 500. Comparatively, Bellevue Life Sciences Acquisition has a beta of -0.08, indicating that its stock price is 108% less volatile than the S&P 500. Does the media refer more to NXL or BLAC? In the previous week, Nexalin Technology had 1 more articles in the media than Bellevue Life Sciences Acquisition. MarketBeat recorded 1 mentions for Nexalin Technology and 0 mentions for Bellevue Life Sciences Acquisition. Nexalin Technology's average media sentiment score of 1.89 beat Bellevue Life Sciences Acquisition's score of 0.00 indicating that Nexalin Technology is being referred to more favorably in the media. Company Overall Sentiment Nexalin Technology Very Positive Bellevue Life Sciences Acquisition Neutral Do insiders and institutionals believe in NXL or BLAC? 0.6% of Nexalin Technology shares are owned by institutional investors. Comparatively, 55.3% of Bellevue Life Sciences Acquisition shares are owned by institutional investors. 24.0% of Nexalin Technology shares are owned by insiders. Comparatively, 33.7% of Bellevue Life Sciences Acquisition shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Do analysts rate NXL or BLAC? Nexalin Technology presently has a consensus price target of $5.00, suggesting a potential upside of 316.04%. Given Nexalin Technology's stronger consensus rating and higher probable upside, research analysts clearly believe Nexalin Technology is more favorable than Bellevue Life Sciences Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Bellevue Life Sciences Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in NXL or BLAC? Nexalin Technology received 2 more outperform votes than Bellevue Life Sciences Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformNexalin TechnologyOutperform Votes250.00% Underperform Votes250.00% Bellevue Life Sciences AcquisitionN/AN/A Which has better earnings and valuation, NXL or BLAC? Bellevue Life Sciences Acquisition has lower revenue, but higher earnings than Nexalin Technology. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNexalin Technology$131.07K157.51-$4.65M-$0.83-1.45Bellevue Life Sciences AcquisitionN/AN/AN/AN/AN/A Is NXL or BLAC more profitable? Bellevue Life Sciences Acquisition has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,407.98%. Bellevue Life Sciences Acquisition's return on equity of 0.00% beat Nexalin Technology's return on equity.Company Net Margins Return on Equity Return on Assets Nexalin Technology-3,407.98% -187.59% -167.21% Bellevue Life Sciences Acquisition N/A N/A N/A SummaryNexalin Technology beats Bellevue Life Sciences Acquisition on 8 of the 13 factors compared between the two stocks. Get Bellevue Life Sciences Acquisition News Delivered to You Automatically Sign up to receive the latest news and ratings for BLAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLAC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLAC vs. The Competition Export to ExcelMetricBellevue Life Sciences AcquisitionHolding Offices IndustryManufacturing SectorNASDAQ ExchangeMarket Cap$6.75M$480.45M$2.04B$8.63BDividend YieldN/A7.70%2.61%4.18%P/E RatioN/A2.5322.6420.01Price / SalesN/A83.5455.86157.94Price / CashN/A69.0151.7234.64Price / BookN/A6.402.124.70Net IncomeN/A$35.76M-$292.00M$248.05M7 Day Performance22.79%2.19%1.51%2.62%1 Month Performance33.60%3.54%12.90%6.32%1 Year Performance-84.47%42.66%17.94%13.78% Bellevue Life Sciences Acquisition Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLACBellevue Life Sciences AcquisitionN/A$1.67+15.2%N/A-84.5%$6.75MN/A0.00N/AGap UpHigh Trading VolumeNXLNexalin Technology2.8456 of 5 stars$1.26-1.2%$5.00+298.4%+98.3%$21.56M$131.07K-1.963Gap UpQTIQT ImagingN/A$0.79flatN/A+11.9%$21.44M$4.00M0.00N/ALYRALyra Therapeutics3.0507 of 5 stars$15.50-15.9%$100.00+545.2%-12.9%$20.54M$1.19M-10.4050Short Interest ↓Analyst RevisionHigh Trading VolumeFEMYFemasys3.0973 of 5 stars$0.800.0%$8.67+983.5%-21.3%$20.44M$1.70M-0.9930News CoverageAnalyst ForecastCLGNCollPlant Biotechnologies2.9861 of 5 stars$1.78+2.9%$11.50+546.1%-66.6%$20.39M$2.47M-1.1670Positive NewsHigh Trading VolumeALURAllurion Technologies3.4848 of 5 stars$2.73+0.7%$22.83+736.7%-91.2%$20.35M$28.30M-0.23501Positive NewsShort Interest ↓RVPRetractable Technologies1.2771 of 5 stars$0.68+1.4%N/A-42.5%$20.22M$33.75M-1.25240Gap DownBBLGBone Biologics1.3584 of 5 stars$5.56+22.9%N/A-42.4%$18.19MN/A0.002Stock SplitShort Interest ↓NRXSNeurAxis0.9781 of 5 stars$2.43-8.6%N/A-16.4%$17.54M$2.93M-1.3219Short Interest ↑NXGLNEXGEL1.1182 of 5 stars$2.26-5.0%N/A+7.2%$17.30M$10.23M-3.9010Positive News Related Companies and Tools Related Companies NXL Competitors QTI Competitors LYRA Competitors FEMY Competitors CLGN Competitors ALUR Competitors RVP Competitors BBLG Competitors NRXS Competitors NXGL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLAC) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bellevue Life Sciences Acquisition Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bellevue Life Sciences Acquisition With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLAC Stock Free BLAC Stock Alerts